Pyelonephritis - Pipeline Review, H1 2017

Publisher Name :
Date: 31-Mar-2017
No. of pages: 58
Inquire Before Buying

Pyelonephritis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H1 2017, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 5 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pyelonephritis - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc
AstraZeneca Plc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
The Medicines Company
Zavante Therapeutics Inc
Pyelonephritis - Drug Profiles
(avibactam + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meropenem+ vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin tromethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis
Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016
Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016
Jun 02, 2016: Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections
Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
Apr 07, 2016: Merck To Present Data on ZERBAXA at ECCMID 2016
Feb 22, 2016: New Antibiotic Against Drug-Resistant Bacteria Now Available
Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections
Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)
Jun 18, 2014: MerLion completes recruitment in Finafloxacin phase II cUTI trial
Aug 22, 2013: FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma's Lead Antibacterial Candidate Finafloxacin
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation
May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pyelonephritis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pyelonephritis - Pipeline by Achaogen Inc, H1 2017
Pyelonephritis - Pipeline by AstraZeneca Plc, H1 2017
Pyelonephritis - Pipeline by Merck & Co Inc, H1 2017
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2017
Pyelonephritis - Pipeline by The Medicines Company, H1 2017
Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H1 2017
Pyelonephritis - Dormant Projects, H1 2017
Pyelonephritis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Pyelonephritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global and Regional Overactive Bladder Treatment Market Research Report 2017
    Published: 06-Dec-2017        Price: US 3500 Onwards        Pages: 144
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Anticholinergics - Mirabegr......
  • Global Overactive Bladder Treatment Market Data Survey Report 2025
    Published: 29-Nov-2017        Price: US 1500 Onwards        Pages: 87
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). The global Overactive Bladder Treatment market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market s......
  • Global and China Overactive Bladder Treatment Market Research by Company, Type & Application 2013-2025
    Published: 24-Nov-2017        Price: US 2000 Onwards        Pages: 93
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). Market Segment as follows: By Type - Anticholinergics - Mirabegron - Botox By Application - Idiopathic Overactive Bladder - Neurogenic Overactive Bladder......
  • Global Overactive Bladder Treatment Market Research Report 2011-2023
    Published: 21-Nov-2017        Price: US 1800 Onwards        Pages: 86
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). The global Overactive Bladder Treatment market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to d......
  • Global Overactive Bladder Treatment Market Research Report 2017
    Published: 09-Nov-2017        Price: US 2900 Onwards        Pages: 115
    This report studies Overactive Bladder Treatment in Global market, especially in North America, Europe, China, Japan, focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering Astellas Pharma Allergan Pfizer Teva (Activas) Johnson & Johnson Market Segment by Regions, this report splits Global into several key Regions, with consumption, revenue, market share and growth rate of Overactive Bladder T......
  • Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Cystitis which can turn out to be future prospe......
  • Nocturnal Enuresis -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Nocturnal Enuresis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Nocturnal Enuresis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Nocturnal Enuresis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with......
  • Urinary Incontinence - Market Insights, Epidemiology and Market Forecast -2023-7MM
    Published: 01-Nov-2017        Price: US 4950 Onwards        Pages: 77
    DelveInsight's "Urinary Incontinence - Market Insights, Epidemiology and Market Forecast-2023-7MM" Reports provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023. Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage ......
  • Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Interstitial Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Interstitial Cystitis......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs